Cue Biopharma shares fall 4.67% premarket despite reporting new complete response in clinical trial.

Cue Biopharma, Inc. declined 4.67% in premarket trading. The company reported a clinical update on its most advanced asset, CUE-101, which is being evaluated in a Phase 1 study for the treatment of HPV16+ driven recurrent/metastatic head and neck squamous cell carcinoma. The update included a confirmed overall response rate of 50% in patients with a combined positive score (CPS) ≥1, and a 12-month overall survival of 88%.